Originally published as JCO Early Release 10.1200/JCO.2007.13.1391 on March 31 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilson, W. H. Articles by Janik, J. E. Search for Related Content PubMed PubMed Citation Articles by Wilson, W. H. Articles by Janik, J. E. Social Bookmarking                            What's this?

Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers

Wyndham H. Wilson, Kieron Dunleavy, Stefania Pittaluga, Upendra Hegde, Nicole Grant, Seth M. Steinberg, Mark Raffeld, Martin Gutierrez, Bruce A. Chabner, Louis Staudt, Elaine S. Jaffe, John E. Janik

From the Center for Cancer Research, Bethesda, MD; Massachusetts General Hospital, Boston, MA; and the University of Connecticut, Hartford, CT

Corresponding author: Wyndham H. Wilson, MD, PhD, Metabolism Branch, National Cancer Institute, Building 10, Room 4N/115, 9000 Rockville Pike, Bethesda, MD 20892; e-mail: wilsonw{at}mail.nih.gov

Purpose To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (R) infusional therapy in diffuse large B-cell lymphoma (DLBCL) with analysis of germinal center B-cell (GCB) and post-GCB subtypes by immunohistochemistry.

Patients and Methods Phase II study of 72 patients with untreated de novo DLBCL who were at least 18 years of age and stage II or higher. Radiation consolidation was not permitted.

Results Patients had a median age of 50 years (range, 19 to 85) and 40% had a high-intermediate or high International Prognostic Index (IPI). At 5 years, progression-free survival (PFS) and overall survival (OS) were 79% and 80%, respectively, with a median potential follow-up of 54 months. PFS was 91%, 90%, 67%, and 47%, and OS was 100%, 90%, 74%, and 37%, for 0 to 1, 2, 3, and 4 to 5 IPI factors, respectively, at 5 years. The Bcl-2 and MIB-1 biomarkers were not associated with PFS or OS. Based on DA-EPOCH historical controls, rituximab only benefited Bcl-2 positive tumors. Bcl-6 expression was associated with higher PFS whereas GCB exhibited a marginally significant higher PFS compared with post-GCB DLBCL.

Conclusion DA-EPOCH-R outcome was not affected by tumor proliferation and rituximab appeared to overcome the adverse effect of Bcl-2. Bcl-6 may identify a biologic program associated with a superior outcome. Overall, DA-EPOCH-R shows promising outcome in low and intermediate IPI groups. A molecular model of treatment outcome with rituximab and chemotherapy is presented.

published online ahead of print at www.jco.org on March 31, 2008.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Ann. Onc., June 30, 2009; (2009) mdp237v1. [Abstract] [Full Text] [PDF]

				K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright, N. Grant, M. Shovlin, E. S. Jaffe, J. E. Janik, L. M. Staudt, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood, June 11, 2009; 113(24): 6069 - 6076. [Abstract] [Full Text] [PDF]

				New EPOCH in Lymphoma Therapy Journal Watch Oncology and Hematology, June 10, 2008; 2008(610): 2 - 2. [Full Text]